BRPI0611984A2 - uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo - Google Patents

uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo

Info

Publication number
BRPI0611984A2
BRPI0611984A2 BRPI0611984-0A BRPI0611984A BRPI0611984A2 BR PI0611984 A2 BRPI0611984 A2 BR PI0611984A2 BR PI0611984 A BRPI0611984 A BR PI0611984A BR PI0611984 A2 BRPI0611984 A2 BR PI0611984A2
Authority
BR
Brazil
Prior art keywords
manufacture
antibodies
igf
treat
drug
Prior art date
Application number
BRPI0611984-0A
Other languages
English (en)
Inventor
Dalel L Ludwig
Stephen R Plymate
Nick Loizos
Jim Huber
Alessandro Fatatis
Original Assignee
Imclone Systems Inc
Univ Washington
Drexel University College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Univ Washington, Drexel University College Of Medicine filed Critical Imclone Systems Inc
Publication of BRPI0611984A2 publication Critical patent/BRPI0611984A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE ANTICORPOS IGF-IR PARA FABRICAçãO DE UM MEDICAMENTO PARA TRATAR UM TUMOR óSSEO. A invenção fornece usos de um antagonista IGE-IR e/ou PDGFR<244> para fabricação de medicamentos para tratar câncer ósseo, em particular o câncer ósseo metastático. A invenção fornece também anticorpos que se ligam aos PDGFRY humanos e neutralizam a ativação dos receptores. A invenção ainda fornece um método para neutralizar a ativação de PDGFR<244>, e um uso do anticorpo isoladamente ou em combinação com outros agentes na fabricação de medicamentos para tratar uma doença neoplásica.
BRPI0611984-0A 2005-06-17 2006-06-19 uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo BRPI0611984A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69192005P 2005-06-17 2005-06-17
PCT/US2006/023856 WO2006138729A2 (en) 2005-06-17 2006-06-19 Receptor antagonists for treatment of metastatic bone cancer

Publications (1)

Publication Number Publication Date
BRPI0611984A2 true BRPI0611984A2 (pt) 2009-07-07

Family

ID=37571297

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0611984-0A BRPI0611984A2 (pt) 2005-06-17 2006-06-19 uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
BRPI0622073A BRPI0622073A8 (pt) 2005-06-17 2006-06-19 Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0622073A BRPI0622073A8 (pt) 2005-06-17 2006-06-19 Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo

Country Status (21)

Country Link
US (3) US8128929B2 (pt)
EP (4) EP2100618B1 (pt)
JP (4) JP2009501141A (pt)
KR (3) KR101246428B1 (pt)
CN (3) CN101500597A (pt)
BR (2) BRPI0611984A2 (pt)
CA (3) CA2680945C (pt)
CY (3) CY1114603T1 (pt)
DK (2) DK2100614T3 (pt)
ES (2) ES2452115T3 (pt)
HK (1) HK1135917A1 (pt)
HU (1) HUS1700015I1 (pt)
IL (3) IL188151A0 (pt)
LT (1) LTC2100614I2 (pt)
LU (1) LUC00012I2 (pt)
NL (1) NL300869I2 (pt)
PL (2) PL2100614T3 (pt)
PT (2) PT2100614E (pt)
RU (3) RU2008101772A (pt)
SI (2) SI2100614T1 (pt)
WO (1) WO2006138729A2 (pt)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2100614T3 (da) * 2005-06-17 2013-10-28 Imclone Llc Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
WO2009021150A2 (en) * 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US20090280112A1 (en) * 2008-05-05 2009-11-12 The Regents Of The University Of California Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
CN103025369B (zh) 2010-06-07 2016-07-06 安姆根有限公司 药物递送装置
JP2013177317A (ja) * 2010-06-24 2013-09-09 Meneki Seibutsu Kenkyusho:Kk 抗ｐｄｇｆ受容体抗体
JP2013531679A (ja) * 2010-07-02 2013-08-08 メディミューン，エルエルシー 抗体製剤
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
EP2699293B8 (en) 2011-04-20 2022-07-20 Amgen Inc. Autoinjector apparatus
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
SI3045187T1 (sl) 2011-10-14 2019-06-28 Amgen Inc. Injektor in postopek sestave
JP6268097B2 (ja) 2011-11-11 2018-01-24 デューク・ユニヴァーシティ 固形腫瘍治療のための併用薬物療法
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
CN105705519A (zh) 2013-03-06 2016-06-22 梅里麦克制药股份有限公司 抗C-MET串联Fc双特异性抗体
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
LT2976117T (lt) 2013-03-22 2021-02-25 Amgen Inc. Purkštuvas ir surinkimo būdas
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
BR112016008946B1 (pt) 2013-10-24 2022-12-27 Amgen Inc Injetores e método para montar os injetor
EP3501575B1 (en) 2013-10-24 2021-12-01 Amgen Inc. Drug delivery system with temperature-sensitive-control
US10426920B2 (en) * 2013-12-20 2019-10-01 Boston Scientific Scimed, Inc. Integrated catheter system
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
SG10201811702TA (en) 2014-05-07 2019-01-30 Amgen Inc Autoinjector with shock reducing elements
SG10201806528QA (en) 2014-06-03 2018-08-30 Amgen Inc Controllable drug delivery system and method of use
US20170129958A1 (en) * 2014-07-03 2017-05-11 Imclone Llc Combination therapy
JP6480479B2 (ja) 2014-07-03 2019-03-13 イムクローン リミテッド ライアビリティ カンパニー Ｇｉｓｔの治療法
US10695506B2 (en) 2014-10-14 2020-06-30 Amgen Inc. Drug injection device with visual and audio indicators
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
WO2016068803A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
EP3233163B1 (en) 2014-12-19 2021-10-13 Amgen Inc. Drug delivery device with proximity sensor
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
JP2018512184A (ja) 2015-02-27 2018-05-17 アムジエン・インコーポレーテツド 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US20200022917A1 (en) 2015-12-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
MA45493A (fr) * 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh Inhibiteurs d'entrée de hcmv.
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
ES2822084T3 (es) * 2016-07-28 2021-04-29 Elanco Us Inc Anticuerpo antirreceptor alfa del factor de crecimiento derivado de plaquetas canino
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
MX2019010671A (es) 2017-03-09 2019-10-21 Amgen Inc Mecanismo de insercion para dispositivo de administracion de farmacos.
WO2018169779A1 (en) 2017-03-17 2018-09-20 ImClone, LLC Combination therapy for pancreatic cancer
KR102651078B1 (ko) 2017-03-28 2024-03-22 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
WO2019070497A1 (en) 2017-10-04 2019-04-11 Imclone Llc POLY THERAPY AGAINST CANCER
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
EP3706830A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
CN111263651B (zh) 2017-11-16 2022-06-17 安进公司 具有停顿和终点检测的自动注射器
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
WO2019231803A1 (en) 2018-05-31 2019-12-05 Imclone Llc Combination therapy for soft tissue sarcoma
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US20210369982A1 (en) 2018-07-24 2021-12-02 Amgen Inc. Delivery devices for administering drugs
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
EP3866889A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Platform assembly process for drug delivery device
WO2020081479A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MX2021005808A (es) 2018-11-20 2021-07-02 Univ Cornell Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
CN109134655B (zh) * 2018-11-28 2019-02-26 上海复宏汉霖生物技术股份有限公司 一种抗PDGFRα的单克隆抗体及其制备方法和应用
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
JP2022552323A (ja) 2019-10-15 2022-12-15 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) * 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4774321A (en) * 1986-12-01 1988-09-27 Massachusetts Institute Of Technology DP100 EGF and insulin-binding protein from Drosophila cells
EP0308500B1 (en) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
DE68921364T2 (de) 1988-04-16 1995-06-29 Celltech Ltd Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
ATE397659T1 (de) * 1989-02-09 2008-06-15 Us Health Polyklonale antikörper gegen den menschlichen alpha-pdgf-rezeptor und dessen verwendung
US7252929B2 (en) * 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US6228600B1 (en) * 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
JPH05506857A (ja) 1990-04-16 1993-10-07 ローヌ―プーラン　ローラー　インターナショナル　（ホウルディングス）インコーポレイテッド Ｅｇｆレセプタチロシンキナーゼを阻害するスチリル―置換単環式および二環式複素アリール化合物
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
WO1992003152A1 (en) * 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein (igfbp-4)
ES2147729T3 (es) * 1991-01-31 2000-10-01 Cor Therapeutics Inc Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5262308A (en) * 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5869337A (en) * 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
DE69413009T2 (de) 1993-02-25 1999-03-25 Zymogenetics Inc Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
EP0694069A1 (en) * 1993-04-06 1996-01-31 Cedars-Sinai Medical Center Variant insulin-like growth factor i receptor subunits and methods for use thereof
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5597700A (en) * 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
DE69518919T2 (de) * 1994-06-24 2001-03-29 Vladimir P Torchilin Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0861267A4 (en) * 1995-11-14 2000-02-02 Univ Jefferson INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6071891A (en) * 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU763669B2 (en) 1998-09-29 2003-07-31 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
NZ511055A (en) * 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination
KR20010080491A (ko) 1998-11-19 2001-08-22 로즈 암스트롱, 크리스틴 에이. 트러트웨인 티로신 키나제의 비가역적 저해제인ｎ-[4-(3-클로로-4-플루오로-페닐아미노)-7-(3-모르폴린-4-일-프로폭시)-퀴나졸린-6-일]-아크릴아미드
EP1006184A1 (en) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2001006967A1 (en) 1999-07-27 2001-02-01 Michael Miravet Sorribes A device for non-invasively correcting the shape of a human external ear
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
RU2183461C2 (ru) * 2000-05-29 2002-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения сарком мягких тканей
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7071160B2 (en) * 2000-06-15 2006-07-04 Kyowa Hakko Kogyo Co., Ltd. Insulin-like growth factor-binding protein
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
UY27087A1 (es) * 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
IL157705A0 (en) * 2001-03-14 2004-03-28 Genentech Inc Igf antagonist peptides
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2427964T3 (es) 2002-01-18 2013-11-05 Pierre Fabre Medicament Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
ATE510561T1 (de) 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
PL210412B1 (pl) * 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
WO2004013180A2 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
EP1613658B1 (en) 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
RU2241452C1 (ru) * 2003-06-11 2004-12-10 Московский областной научно-исследовательский клинический институт Способ лечения метастазов в кости
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
AU2004263538B2 (en) * 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EA200600234A1 (ru) * 2003-08-13 2006-08-25 Пфайзер Продактс Инк. Модифицированные igf - 1r антитела человека
WO2005018671A1 (ja) * 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
JPWO2005027970A1 (ja) * 2003-09-24 2007-11-15 協和醗酵工業株式会社 癌治療用医薬
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
JP4493485B2 (ja) 2004-04-28 2010-06-30 シャープ株式会社 太陽電池モジュール用配線部材、それを用いた太陽電池モジュールおよび太陽電池モジュール用配線部材の製造方法
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
CA2589885A1 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US20060233814A1 (en) * 2005-04-15 2006-10-19 Immunogen Inc. Elimination of heterogeneous or mixed cell population in tumors
DK2100614T3 (da) * 2005-06-17 2013-10-28 Imclone Llc Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
US20070009970A1 (en) * 2005-07-08 2007-01-11 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
ES2385054T3 (es) * 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
WO2010000008A1 (en) 2008-06-30 2010-01-07 Desi Raymond Richardson Thiosemicarbazone compounds and use thereof
MX2010013190A (es) 2008-07-18 2010-12-20 Hoffmann La Roche Fenilimidazopirazinas novedosas.
DK200900548A (en) 2008-07-18 2010-01-19 Univ Koebenhavn Processes for manufacture of products from plants

Also Published As

Publication number Publication date
IL198869A (en) 2011-09-27
KR101246428B1 (ko) 2013-03-21
HK1135917A1 (en) 2010-06-18
CN101613409A (zh) 2009-12-30
WO2006138729A2 (en) 2006-12-28
CA2612449A1 (en) 2006-12-28
CN101500597A (zh) 2009-08-05
US20090110678A1 (en) 2009-04-30
CY1114603T1 (el) 2016-10-05
PL2100614T3 (pl) 2014-02-28
EP1909819A2 (en) 2008-04-16
EP2100614B8 (en) 2013-11-20
LUC00012I2 (pt) 2017-06-19
EP2100614B1 (en) 2013-10-09
CA2680945C (en) 2014-03-18
CA2680945A1 (en) 2006-12-28
IL198870A (en) 2013-03-24
IL198870A0 (en) 2010-02-17
SI2100618T1 (sl) 2014-03-31
LUC00012I1 (pt) 2017-04-06
EP2100614A3 (en) 2010-02-17
PT2100618E (pt) 2014-04-07
RU2008101772A (ru) 2009-07-27
US8425911B2 (en) 2013-04-23
NL300869I2 (nl) 2017-05-24
PL2100618T3 (pl) 2014-07-31
JP5436883B2 (ja) 2014-03-05
US8574578B2 (en) 2013-11-05
RU2009115364A (ru) 2010-10-27
KR20090027774A (ko) 2009-03-17
US20120034244A1 (en) 2012-02-09
WO2006138729A3 (en) 2009-02-12
LTC2100614I2 (lt) 2018-03-26
DK2100614T3 (da) 2013-10-28
JP5154470B2 (ja) 2013-02-27
CN101612399A (zh) 2009-12-30
HUS1700015I1 (hu) 2017-07-28
IL198869A0 (en) 2010-02-17
CA2678008A1 (en) 2006-12-28
CN101612399B (zh) 2013-11-27
RU2502523C2 (ru) 2013-12-27
JP2009106306A (ja) 2009-05-21
EP1909819A4 (en) 2010-02-17
EP2505205A1 (en) 2012-10-03
CA2678008C (en) 2013-07-30
JP2012179060A (ja) 2012-09-20
BRPI0622073A8 (pt) 2017-09-19
BRPI0622074A2 (pt) 2011-07-19
JP2009501141A (ja) 2009-01-15
BRPI0622073A2 (pt) 2011-07-19
CY2017013I1 (el) 2017-07-12
KR101246504B1 (ko) 2013-03-26
CY1115076T1 (el) 2016-12-14
DK2100618T3 (en) 2014-03-03
CY2017013I2 (el) 2017-07-12
RU2009115363A (ru) 2010-10-27
BRPI0622074A8 (pt) 2017-10-10
PT2100614E (pt) 2013-12-16
SI2100614T1 (sl) 2014-03-31
ES2452115T3 (es) 2014-03-31
RU2455026C2 (ru) 2012-07-10
EP2100618A2 (en) 2009-09-16
KR20080047529A (ko) 2008-05-29
KR20090027773A (ko) 2009-03-17
JP2009102444A (ja) 2009-05-14
IL188151A0 (en) 2008-03-20
US8128929B2 (en) 2012-03-06
EP2100618B1 (en) 2014-02-12
LTPA2017011I1 (lt) 2017-05-10
ES2435727T3 (es) 2013-12-23
CN101613409B (zh) 2014-06-04
US20120027767A1 (en) 2012-02-02
RU2455026C3 (ru) 2020-04-08
EP2100614A2 (en) 2009-09-16
EP2100618A3 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
UA94899C2 (ru) Фиксированное дозирование антител к her
PA8635501A1 (es) Uso de un anticuerpo para el tratamiento del lupus
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CL2008002565A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente al dominio extracelular de cxcr5/receptor de linfoma de burkitt (blr1)/cd185/mdr15/mgc117347 humano; molécula de ácido nucleico aislada que lo codifica; vector que comprende a dicha molécula de ácido nucleico; célula huésped aislada que comprende a dicho vector; uso médico de dicho anticuerpo; y composición farmacéutica que lo comprende.
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
CY1115003T1 (el) Θεραπευτικη χρηση των αντισωματων αντι-cs1
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
UY27291A1 (es) Inmunoconjugados de anticuerpos cd44 citotóxicos
TH84335A (th) แอนติบอดีของ dr5 และการใช้สิ่งนั้น
BRPI0512889A (pt) uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia
BR112015022967A8 (pt) anticorpos anti-gd2 de alta afinidade.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF WASHINGTON (US) , DREXEL UNIVERSITY

Free format text: NOME ALTERADO DE: IMCLONE SYSTEMS INCORPORATED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2213 DE 04/06/2013.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/22 (2006.01)